Analysis On Anti-cancer Drugs Patent Early Warning

Objective:In recent years,the threat of cancer to human health is getting more and more serious.The growing morbidity and mortality have promoted the development of global anti-cancer drugs.However,with the expansion of the scope of patent layout,there are a lot of patent infringements and conflicts between the different institutions in this field,which seriously interfere the research and development of anti-cancer drugs.By the patent early warning in the field,the researchers can clear the research direction and improve the efficiency in research,and it also can avoid duplication of research and save the costs.Methods:The analysis is performed based on the data from Derwent innovation index and combined with the professional knowledge in this field.The patent analysis methods and technology efficiency matrix have been used to analysis the pharmaceutical indications,mechanisms,targets and other technical features in the patent data.The results are displayed by visualization technology.The patent information of the main patentees in the field of anticancer drugs from 2012-2017 are analyzed from the perspective of patent early warning.Results:1.At this stage,the number of patent applications in this field has changed steadily with slowly growth rate.There are 5 universities and national research institutions of China among the top 10 patentees,and the remaining 5 are multinational pharmaceutical companies in abroad.China Pharmaceutical University and Roche are the representative of the patentees.China,the United States,Europe and Japan are the main patent layout area.The morbidity and economic level are the important reference conditions when the patentees are in the regional layout.For the support of national policy,the patent applications of the domestic patentees have increased rapidly in recent years.2.Breast cancer,lung cancer and prostate cancer are the most concerned cancers by the main patentees,which pay most attention to the morbidity and mortality of cancer in China and the United States.Protein kinase inhibitors,immunomodulators,monoclonal antibodies,apoptosis inducers and angiogenesis inhibitors are paid much attention by the patentees.Novartis and Bayer have accumulated larger advantage in the field of protein kinase inhibitors.Roche and Genentech Inc are the leaders of the monoclonal antibodies.China Pharmaceutical University has a larger advantage in the field of apoptosis inducers,angiogenesis inhibitors and cell cycle inhibitors.EGFR is the most focused target.Novartis has the largest number of target types.Compounds and the derivatives are the main technical direction.Chinese herbal extracts have received increasing attention as anti-cancer drugs or the auxiliary ingredients.3.The studies on compounds,new uses,and combined drug treatment of protein kinase inhibitors have the largest number of patents in the fields of lung cancer,breast cancer,and prostate cancer.Monoclonal antibodies have attracted attention in the treatment of lung cancer,breast cancer,and ovarian cancer,with few researches in the fields of thyroid cancer and brain cancer.The most in-depth study of cancer is breast cancer,which involve research on compounds,new uses,combined drug treatment and pharmaceutical preparations.Conclusions:1.The competition in the field of anti-cancer drugs is fierce.The institutions who have strong scientific research strength continue to increase the investment.Therefore,the researchers should pay more attention to the research of the main patentees such as China Pharmaceutical University,Roche and Novartis.The competitiveness of patentees in this field in China has been continuously improved.Patentees in abroad are very comprehensive in regional layout,and have a stronger sense of protection of intellectual property rights.2.The use of monoclonal antibodies and protein kinase inhibitors with specific targets for the treatment of lung cancer and breast cancer is the current research hotspot.It is prone to arise patent infringements,and the researchers must remain vigilant.The study direction of the patentee is closely related to the morbidity and mortality of cancer.At present,the morbidity of cancer in China and the United States has a greater impact on patentees.The research direction of patentees in abroad has basically changed from traditional chemotherapy drugs to targeted therapeutic drugs,and patents involving chemotherapeutic drugs still occupy a significant proportion in domestic patents.Foreign patentees have found the superior targets,but the research of domestic patentees have fewer advantageous targets for the relatively scattered on the target.3.Governments,industry associations,universities and national scientific research institutes and enterprises should strengthen cooperation to jointly establish patent early warning mechanisms.They also should define the respective functions and give full play to the advantages.To grasp the development trend of various technologies,the researchers must pay more attention to the progress of small molecule inhibitors and immunotherapy in the further development of traditional therapeutic drugs.During the drug development,researchers should promote the strengths as much as possible to avoid shortcomings.We should give full play to the advantages of drug carriers and traditional Chinese medicine.Institutions should formulate research strategies suitable for the further development.